Application of ureaplasma urealyticum and ureaplasma parvum target genes, primer probe combination and kit
Through the combination of multiple fluorescence PCR analysis method and target gene primer probe, the problem of poor detection specificity of gonococcal, microurea and ureaplasma in the prior art is solved, and rapid and accurate distinction and detection are achieved, with high Sensitivity and stability.
Patent Information
- Application Number
- CN202411422566.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-12-06
AI Technical Summary
The existing nucleic acid amplification detection methods have poor specificity for gonococci, microurea and ureaplasma ureaplasma, cumbersome, sample requirements are strict, and the detection reagents need to be frozen and preserved, making it difficult to achieve rapid and accurate distinction and detection.
Multiple fluorescence PCR analysis method is used to detect targets on different pathogens, provide a combination of target genes and primer probes, and design specific primers and probes to simultaneously detect and distinguish gonococcal and microureagen in a single tube reaction system. and ureahydroplasma.
It has achieved detection of sensitivity to gonococci, microurea and ureaplasma ureaplasma to 400copies/mL, with good specificity and more accurate detection, and can be stored at 2 to 8℃ for 12 months, simplifying the operation process .
Smart Images

Figure BDA0005081246080000041 
Figure BDA0005081246080000042 
Figure BDA0005081246080000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pathogen molecular detection, and in particular to the application of Ureaplasma urealyticum and Ureaplasma microcarpa target genes, primer probe combinations and kits. Background Art
[0002] Neisseria gonorrhoeae is the pathogen of the classic sexually transmitted disease gonorrhea, which is widely prevalent worldwide. Gonorrhea has a short incubation period and can cause acute and chronic genital tract inflammation. In severe cases, it can lead to infertility, ectopic pregnancy, fetal maldevelopment and other consequences. However, among adults, 5-20% of males and 50% of females are asymptomatic and are often not discovered until complications occur, missing the best time for cure. Therefore, gonorrhea has become a major health problem at home and abroad.
[0003] Human ureaplasma is a prokaryotic cell microorganism belonging to the genus Ureaplasma in the family Mycoplasma. It has no cell wall and is the smallest microorganism found so far that can reproduce in an inanimate culture medium. It mainly exists in the urogenital tract and respiratory tract. It is a conditionally pathogenic microorganism that can invade the host mucosa when the body is immunosuppressed. The main transmission route is sexual transmission, and it can also be vertically transmitted from mother to child, or through body fluids at birth. At present, it is known that human ureaplasma is mainly divided into two biota (Ureaplasma microcarpa and Ureaplasma urealyticum) and 14 serotypes. Ureaplasma microcarpa includes serotypes 1, 3, 6 and 14, while the remaining 10 serotypes belong to Ureaplasma urealyticum. The difference in pathogenicity of human ureaplasma may be related to different biota, serotypes and host factors, but the mechanism is not yet clear. A lot of evidence shows that Ureaplasma microcarpa is easy to be carried, and typing is helpful for studying its pathogenic mechanism.
[0004] Traditional methods for detecting Neisseria gonorrhoeae and Ureaplasma hominis include culture detection, antigen detection and nucleic acid amplification detection. Nucleic acid amplification detection is simple, fast and reliable, but most existing nucleic acid amplification detection kits have the defects of poor specificity, few target combination methods, strict sample requirements, the need to design multiple sets of primers and complicated operations, and the detection reagents need to be frozen for storage. Therefore, there is a need in this field for a product that can simply, quickly and accurately distinguish the above pathogens. Summary of the invention
[0005] In view of this, the present invention provides the application of target genes of Ureaplasma urealyticum and Ureaplasma parvum, primer probe combination and kit. The kit provided by the present invention mainly uses a multiplex fluorescence PCR analysis method to detect different pathogens by detecting targets on different pathogens, thereby simultaneously realizing the detection and differentiation of gonococci, Ureaplasma parvum and Ureaplasma urealyticum in a single tube reaction system.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides the use of a target gene in preparing a product for identifying Ureaplasma urealyticum and Ureaplasma microphylla:
[0008] The target genes respectively have:
[0009] (I), a nucleotide sequence for identifying Ureaplasma urealyticum as shown in SEQ ID NO.11, a nucleotide sequence for identifying Ureaplasma microti as shown in SEQ ID NO.12; and / or
[0010] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or
[0011] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or
[0012] (IV) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of (I), (II) or (III).
[0013] The present invention also provides a primer-probe combination, which comprises:
[0014] (I), an upstream primer for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.1; and
[0015] A downstream primer for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.2; and
[0016] A probe for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.3; and / or
[0017] (II), an upstream primer for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.4; and
[0018] A downstream primer for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.5; and
[0019] A probe for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.6; and / or
[0020] (III), an upstream primer for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.4; and
[0021] A downstream primer for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.5; and
[0022] A probe for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.7; or
[0023] (IV) a nucleotide sequence encoding the same protein as the nucleotide sequence shown in any one of (I) to (III) but different from the nucleotide sequence shown in any one of (I) to (III) due to the degeneracy of the genetic code; or
[0024] (V) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in any one of (I) to (IV), and a nucleotide sequence having the same or similar function as the nucleotide sequence shown in any one of (I) to (IV); or
[0025] (VI) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of any one of (I) to (V).
[0026] In some specific embodiments of the present invention, the fragment amplified by the primer pair for detecting the Ureaplasma urealyticum is shown as SEQ ID NO.11; the fragment amplified by the primer pair for detecting the Ureaplasma microphylla is shown as SEQ ID NO.12.
[0027] In some specific embodiments of the present invention, the primer-probe combination further comprises a primer pair and a probe for amplifying and detecting an internal standard gene;
[0028] The internal standard gene includes one or more of β-globin, RNase P gene, Actin or GAPDH.
[0029] In some specific embodiments of the present invention, the primer-probe combination further comprises:
[0030] (I), an upstream primer for detecting an internal standard gene having a nucleotide sequence as shown in SEQ ID NO.8; and
[0031] A downstream primer for detecting an internal standard gene having a nucleotide sequence as shown in SEQ ID NO.9; and
[0032] A probe for detecting an internal standard having a nucleotide sequence as shown in SEQ ID NO.10; or
[0033] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or
[0034] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or
[0035] (IV) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of (I), (II) or (III).
[0036] In some specific embodiments of the present invention, the probe comprises a fluorescent group; the fluorescent group comprises one or more of FAM, HEX, ROX, VIC, CY5 or Cy5.5.
[0037] In some specific embodiments of the present invention, the probe as shown in SEQ ID NO.3 is connected to a FAM fluorescent group; the probe as shown in SEQ ID NO.6 is connected to a ROX fluorescent group; the probe as shown in SEQ ID NO.7 is connected to a Cy5 fluorescent group; the probe as shown in SEQ ID NO.10 is connected to a HEX fluorescent group.
[0038] The present invention also provides the use of the primer-probe combination in preparing a reagent or a kit for detecting and / or identifying gonococci, ureaplasma parvum and ureaplasma urealyticum.
[0039] The present invention also provides the use of the primer-probe combination in preparing a reagent or a kit for detecting genital tract inflammation.
[0040] The present invention also provides a combined reagent, comprising the primer-probe combination.
[0041] The present invention also provides a kit, comprising any of the following items and PCR reaction reagents:
[0042] (I), the primer-probe combination; and / or
[0043] (II), the combined reagent.
[0044] In some specific embodiments of the present invention, the PCR reaction reagents include any one or more of the following: dNTPs, DNA polymerase, UDG enzyme, PCR enhancer, and magnesium ions.
[0045] In some specific embodiments of the present invention, the PCR enhancer comprises DMSO.
[0046] In some embodiments of the invention, the magnesium ion comprises MgCl2.
[0047] In some specific embodiments of the present invention, the reaction system of the kit comprises:
[0048]
[0049] In some specific embodiments of the present invention, the kit further comprises a negative control and a positive control; the negative control comprises an internal standard plasmid; the positive control comprises Neisseria gonorrhoeae, Ureaplasma parvum, Ureaplasma urealyticum and an internal standard plasmid.
[0050] In some specific embodiments of the present invention, the PCR reaction procedure includes:
[0051]
[0052]
[0053] The present invention includes but is not limited to providing the following beneficial effects:
[0054] The present invention provides the application of target genes of Ureaplasma urealyticum and Ureaplasma microtyping, primer probe combination and kit. The kit provided by the present invention mainly uses a multiplex fluorescence PCR analysis method to detect different pathogens by detecting targets on different pathogens, thereby simultaneously realizing the detection and differentiation of gonococci, Ureaplasma microtyping and Ureaplasma urealyticum in a single tube reaction system. The kit of the present invention has a detection sensitivity of 400 copies / mL, good specificity, more accurate detection, and can be stored at 2-8°C for up to 12 months. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0056] Figure 1 The figure shows the detection results of gonococci, Ureaplasma parvum and Ureaplasma urealyticum by the kit of Preparation Example 1 of the present invention; wherein the blue represents the amplification curve of gonococci, the yellow represents the amplification curve of Ureaplasma parvum, the purple represents the amplification curve of Ureaplasma urealyticum, and the green represents the amplification curve of the internal standard;
[0057] Figure 2 The figure shows the sensitivity result of the kit of the present invention in detecting gonococci;
[0058] Figure 3 The figure shows the sensitivity result of the kit of the present invention in detecting Ureaplasma microti;
[0059] Figure 4 The figure shows the sensitivity result of the kit of the present invention in detecting Ureaplasma urealyticum;
[0060] Figure 5The specific test result diagram of the kit of the present invention is shown; wherein, blue represents the amplification curve of gonococci, yellow represents the amplification curve of Ureaplasma parvum, purple represents the amplification curve of Ureaplasma urealyticum, and green represents the amplification curve of the internal standard;
[0061] Figure 6 The figure shows the results of the single detection of Ureaplasma urealyticum comparative primers;
[0062] Figure 7 The multiple result graph of the comparative primers for Ureaplasma urealyticum is shown; among them, blue represents the amplification curve of Neisseria gonorrhoeae, yellow represents the amplification curve of Ureaplasma parvum, purple represents the amplification curve of Ureaplasma urealyticum, and green represents the amplification curve of the internal standard. DETAILED DESCRIPTION
[0063] The present invention discloses the application of Ureaplasma urea and Ureaplasma microcarpa target genes, primer probe combination and kit, and those skilled in the art can learn from the content of this article and appropriately improve the process parameters to achieve. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described by preferred embodiments, and relevant personnel can obviously change or appropriately change and combine the method and application described herein without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.
[0064] The present invention aims to provide a detection kit for gonococci, ureaplasma parvum and ureaplasma urealyticum, which can quickly and accurately distinguish different pathogens. The present invention has the advantages of high sensitivity, good specificity, and can be stored at 2-8°C.
[0065] The present invention provides a kit for detecting gonococci, ureaplasma parvum and ureaplasma urealyticum, comprising specific primers and probes. The gonococcal primers and probes are designed in the conserved region of the cryptic plasmid gene:
[0066] The nucleotide sequence of the gonococcal upstream primer is (SEQ ID NO. 1): 5'-ACACCCAACC CGACCTCTTCTT-3';
[0067] The nucleotide sequence of the downstream primer for gonococci is (SEQ ID NO. 2): 5'-GCGGCGGATT GACTTGGATGT-3';
[0068] The nucleotide sequence of the gonococcal probe is (SEQ ID NO. 3): 5′-CGGCGTTTGATGGCGGCAGCGTAAGAGC-3′;
[0069] Comparison of urease genes of 14 serotypes of human Ureaplasma revealed that the homology between Ureaplasma parvum (4 serotypes) was 99.3%, the homology between Ureaplasma urealyticum (10 serotypes) was 99.6%, and the homology between Ureaplasma parvum and Ureaplasma urealyticum was 89.7%. We designed primer probes in specific regions to distinguish the two biota. Ureaplasma urealyticum and Ureaplasma parvum share upstream and downstream primers, and use different probes to distinguish them:
[0070] The nucleotide sequence of the Ureaplasma microti upstream primer is (SEQ ID NO. 4): 5'-CTAAATATACAATTAACCCAGCTATTGC-3';
[0071] The nucleotide sequence of the Ureaplasma microti downstream primer is (SEQ ID NO.5): 5'-GGTTTTGCACCAAAGAATTTAGGTTCTC-3';
[0072] The nucleotide sequence of the Ureaplasma microti probe is (SEQ ID NO. 6): 5′-GTGTTGATTCTTATATTGGTTCACTAGAAGTT-3′;
[0073] The nucleotide sequence of the Ureaplasma urealyticum upstream primer is (SEQ ID NO. 4): 5'-CTAAATATACAATTAACCCAGCTATTGC-3';
[0074] The nucleotide sequence of the Ureaplasma urealyticum downstream primer is (SEQ ID NO.5): 5'-GGTTTTGCACCAAAGAATTTAGGTTCTC-3';
[0075] The nucleotide sequence of the Ureaplasma urealyticum probe is (SEQ ID NO. 7): 5′-CATGGTATTGACTCATACGTTGGATCAAT-3′;
[0076] The internal standard is a human internal standard gene, for example, β-globin, RNase P gene, Actin and GAPDH gene can be used. In a specific embodiment, the internal standard is the β-globin gene, and the internal standard primer probe is as follows:
[0077] The nucleotide sequence of the internal standard upstream primer is (SEQ ID NO. 8): 5′-CTCAGTGTGGCA AAGGTGCC-3′;
[0078] The nucleotide sequence of the internal standard downstream primer is (SEQ ID NO.9): 5′-GAAGGCTCATGG CAAGAAAGTG-3′;
[0079] The nucleotide sequence of the internal standard probe is (SEQ ID NO. 10): 5′-GGTTGTCCAGGTGAGCCAGGCCATCACT-3′;
[0080] The reporter fluorescent group of each probe is different, for example, FAM, HEX, ROX, VIC, Cy5 and Cy5.5 can be used. In a specific embodiment, the reporter fluorescent group of the gonococcal probe is FAM, the reporter fluorescent group of Ureaplasma microphylla is ROX, the reporter fluorescent group of Ureaplasma urealyticum is Cy5, and the reporter fluorescent group of the internal standard is HEX.
[0081] Ureaplasma urealyticum target sequence 5'-3' (SEQ ID NO.11):
[0082] CTAAATATACAATTAACCCAGCTATTGCTCATGGTATTGACTCATACGTTGGATCAATCGAAGTAGGAAAATTAGCTGATATTGTTGCATGAGAACCTAAATTCTTTGGTGCAAAACC
[0083] Ureaplasma parvum target sequence 5'-3' (SEQ ID NO.12):
[0084] CTAAATATACAATTAACCCAGCTATTGCACATGGTGTTGATTCTTATATTGGTTCACTAGAAGTTGGTAAATTAGCTGATATTGTTGCTTGAGAACCTAAATTCTTTGGTGCAAAACC
[0085] The kit of the present invention comprises a PCR reaction solution, wherein the PCR reaction solution comprises a PCR reaction solution 1 and a PCR reaction solution 2, wherein the PCR reaction solution 1 comprises the primer-probe combination, dNTPs, DNA polymerase, UDG enzyme, and PCR enhancer; and the PCR reaction solution 2 comprises magnesium ions.
[0086] Specifically, the dNTPs are a combination of dATP, dGTP, dCTP, and dUTP, wherein the concentration of dATP is 0.1 to 0.3 mM, the concentration of dGTP is 0.1 to 0.3 mM, the concentration of dCTP is 0.1 to 0.3 mM, and the concentration of dUTP is 0.1 to 0.3 mM.
[0087] Specifically, the concentration of the DNA polymerase is 0.0125-0.0625 U / μL. In a specific embodiment, the DNA polymerase may be Tth enzyme.
[0088] Specifically, the UDG enzyme concentration is 0.00375-0.0125 U / μL.
[0089] Specifically, the PCR enhancer is DMSO, and the concentration is 0.0125% to 0.0375% (DMSO to total volume ratio).
[0090] Specifically, the magnesium ion concentration is 1.5 mM to 3 mM.
[0091] Specifically, the kit further comprises a positive quality control and a negative quality control. The positive quality control is composed of a fragment plasmid of a cryptic plasmid gene of gonococci, a fragment plasmid of a ureaplasma urease gene, a fragment plasmid of a ureaplasma urealyticum urease gene, and a β-globin gene fragment plasmid, and the negative quality control is a β-globin gene fragment plasmid.
[0092] Unless otherwise specified, the use of the Ureaplasma urealyticum and Ureaplasma microti target genes, the primer-probe combination, and the raw materials and reagents used in the kit provided by the present invention can all be purchased from the market.
[0093] The present invention will be further described below in conjunction with embodiments:
[0094] Preparation Example 1 Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum detection kit
[0095] This embodiment provides a detection kit for Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum, including the following components, see Table 1:
[0096] Table 1 Main components of the kit
[0097]
[0098] Preparation Example 2 Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum detection kit
[0099] This embodiment provides a detection kit for Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum, including the following components, see Table 2:
[0100] Table 2 Main components of the kit
[0101]
[0102] Preparation Example 3 Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum detection kit
[0103] This embodiment provides a detection kit for Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum, including the following components, see Table 3:
[0104] Table 3 Main components of the kit
[0105]
[0106]
[0107] Comparative Example Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum Detection Kit
[0108] Based on the kit of Example 1, the specific primers and probes therein were replaced with the primer and probe sequences shown in Table 4.
[0109] Table 4 Comparative Example Primer Probe Sequences
[0110] name serial number 5'-3' Upstream primer SEQ ID NO.13 AATGAAACTCAGCAACTCCAAATCT Downstream primer SEQ ID NO.14 CCGTTTGCAGTTTTCTTTAATTTCT Probe SEQ ID NO.15 GCTGCCGTTGACTACAACGACTTAGAAAAC
[0111] Example Qualitative Detection of Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum
[0112] 1. Reagent preparation
[0113] According to the number of samples to be tested, negative quality control and positive quality control, take the corresponding amount of PCR reaction solution 1 and PCR reaction solution 2 according to the ratio of the kit in Preparation Examples 1 to 3 (20 μL / person PCR reaction solution 1 + 20 μL / person PCR reaction solution 2), mix them thoroughly to form a PCR-MIX mixed solution, and set aside after instantaneous centrifugation.
[0114] 2. Sample processing
[0115] (1) Rinse the swab to be tested in 1 mL of saline and keep the liquid for later use, or directly test the urine sample.
[0116] (2) Take 600 μL of the rinsed liquid sample or urine sample, and use the magnetic bead nucleic acid extraction reagent (registration number: Yu Zheng Xie Bei 20180037) produced by Zhengzhou Antu Biotechnology Co., Ltd. to extract the nucleic acids of gonococci, Ureaplasma parvum and Ureaplasma urealyticum from the sample to be tested as the extracted DNA of the sample to be tested, and set aside;
[0117] (3) At the same time, take 600 μL of negative / positive quality control products and use the magnetic bead nucleic acid extraction reagent of Zhengzhou Antu Biotechnology Co., Ltd. to extract the DNA nucleic acid of negative and positive quality control products for later use;
[0118] (4) Take several PCR reaction tubes, add 40 μL of PCR-MIX mixed solution, then add 40 μL of the extracted sample DNA and 40 μL of the negative / positive control nucleic acid product, respectively, cover the tubes (after removing bubbles), and centrifuge for 10 seconds.
[0119] 3. Fluorescence PCR reaction
[0120] (1) Place the PCR reaction tube into the sample slot of the thermal amplification instrument and set the names of the samples to be tested in the corresponding order;
[0121] (2) Fluorescence detection channel selection: select FAM / ROX / Cy5 channel to detect target; select HE X channel to detect internal standard;
[0122] (3) PCR reaction program: 50℃2min; 95℃2min; (95℃10s, 60℃22s, 45 cycles); 40℃10s.
[0123] (4) Results analysis
[0124] After the PCR reaction is completed, the test result is determined based on the Ct value. The intersection of the amplification curve and the threshold line is called the Ct value (i.e., cycle threshold, which refers to the number of cycles experienced when the fluorescent signal in the PCR reaction tube reaches the set threshold); the instrument software can determine the test result based on the Ct value of each sample. For samples with a measured Ct value ≤38, the report is positive; for samples with a measured Ct value >38 and a positive internal standard test (Ct value ≤35), the report is less than the detection limit; for samples with no Ct value and a positive internal standard test (Ct value ≤35), the report is negative; if the internal standard Ct value is >35 or not displayed, the test result of the sample is invalid, the cause should be found and eliminated, and the sample should be tested again.
[0125] The PCR test results of Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum are shown in Table 5. Figure 1 As shown, the kit of the present invention can perform good detection on the three pathogens.
[0126] Table 5 Qualitative detection of Neisseria gonorrhoeae, Ureaplasma parvum and Ureaplasma urealyticum
[0127]
[0128]
[0129] Effect Example 1 Sensitivity Detection
[0130] The kit in Preparation Example 1 was used to perform sensitivity tests on each target according to the method in the example. The concentrations of the samples to be tested were 10800, 3600, 1200, and 400 copies / mL, respectively, to simulate clinical samples and perform multiplex PCR tests. The results are shown in FIG. Figures 2 to 4 As shown, it is shown that each channel can still accurately detect samples as low as 400 copies / mL, with a detection rate of 100%, indicating that the sensitivity of the kit of the present invention is 400 copies / mL.
[0131] Effect Example 2 Specificity Detection
[0132] The kit in Preparation Example 1 was used, and the samples to be tested in the embodiment were replaced with common pathogens of the reproductive tract and other pathogens with similar infection symptoms, such as Chlamydia trachomatis (1E+7 copies / mL), herpes simplex virus type 1 (1E+7 copies / mL), Group B Streptococcus (1E+6 CFU / mL), Neisseria meningitidis (1E+6 CFU / mL), Mycoplasma genitalium (1E+7 copies / mL), Mycoplasma hominis (1E+7 copies / mL), human papillomavirus type 16 (1E+7 copies / mL), human cytomegalovirus (1E+7 copies / mL), Mycoplasma pneumoniae (1E+7 copies / mL), Lactobacillus casei (1E+6 CFU / mL), Gardnerella vaginalis (1E+6 CFU / mL), and Candida albicans (1E+6 CFU / mL), and PCR detection was performed. The test results are as follows: Figure 5 As shown, the blue line represents the gonococcal amplification curve, and the gonococcal test result is negative; the yellow line represents the Ureaplasma microamplification curve, and the Ureaplasma microamplification result is negative; the purple line represents the Ureaplasma urealyticum amplification curve, and the Ureaplasma urealyticum test result is negative; the green line represents the internal standard. The present invention has no cross reaction with common pathogens of the reproductive tract and other pathogens with similar infection symptoms (such as Chlamydia trachomatis, herpes simplex virus, group B streptococcus, Neisseria meningitidis, Mycoplasma genitalium, Mycoplasma hominis, human papillomavirus type 16, human cytomegalovirus, Mycoplasma pneumoniae, Lactobacillus paracasei, Gardnerella vaginalis, Candida albicans).
[0133] Effect Example 3: Stability Test
[0134] The reagent can be stored at 2-8°C, and its real-time stability is evaluated by a 37°C thermal stability acceleration test. The reagent is accelerated at 37°C for 0, 7, 14, and 21 days. The reagent kit in Preparation Example 1 is used to detect three samples of high, medium, and low concentrations according to the method of the embodiment (gonococcal concentrations are 4E+4 / mL, 4000 / mL, and 400 / mL, respectively; Ureaplasma microti and Ureaplasma urealyticum concentrations are 5E+4CCU / mL, 5000CCU / mL, and 500CCU / mL, respectively). The difference in Ct value compared with that on day 0 is no more than 1.33 Ct, which is small, indicating that it is stable. The results are shown in the following table:
[0135] Table 6 Stability test
[0136]
[0137] Effect Example 4 Selection of Primer Probe Sequences
[0138] In the multiple pathogen detection system, there are many primer-probe sequences in the same reaction, dimers will be formed between primers and (or) probes, and primers and probes will interfere with each other. These factors have an impact on sensitivity. The inventors also designed some other primer-probe combinations (sequences are shown in Table 4), using the kit in the comparative example to detect gonococci, Ureaplasma parvum and Ureaplasma urealyticum according to the method of the embodiment. The specific test results are shown in Figure 4. Figures 6-7 As can be seen from the figure, the comparative primer probe of Ureaplasma urealyticum has a good detection result in the single detection system, but in the multiplex system, its detection is affected and the Ct value performance is poor, which further illustrates the superiority of the combination of the present invention.
[0139] Effect Example 5 Comparison of different detection methods
[0140] Experimental groups:
[0141] Experimental group: Take samples of different concentrations (clinical samples with known concentrations are diluted 4 times to 6400, 1600, 400, and 100 copies / mL), use the kit in Preparation Example 1, and detect according to the method of the embodiment.
[0142] Control group: Take samples of different concentrations to be tested (clinical samples with known concentrations are diluted 4 times to 6400, 1600, 400, and 100 copies / mL), and compare with the detection method in the published patent CN200910164977 (positive judgment value 40). The primer probe sequences are shown in Table 7, the reaction system is shown in Table 8, and the PCR amplification program is: 50°C 2min; 95°C 10min; 95°C 10s, 60°C 50s, 40 cycles.
[0143] The results are shown in Table 9. It can be seen from the table that the gonococci of the present invention can still be stably detected when 400 copies / mL is detected (experimental group), but the control group has missed detection, so the detection ability of the present invention is better than that of the comparison reagent.
[0144] Table 7 Primer probe sequences for control group
[0145] name serial number 5'-3' Upstream primer SEQ ID NO.16 CTTCTCGGGTGGCGAGTGG Downstream primer SEQ ID NO.17 CCAGTAATTCCGATTAACGCTCG Probe SEQ ID NO.18 CGGGTCTGAGAGGATGATCCGCC
[0146] Table 8 Control group reaction system
[0147]
[0148] Table 9 Comparison of different detection methods
[0149]
[0150]
[0151] Note: Negative (-), positive (+).
[0152] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of target genes in the preparation of products for identifying Ureaplasma urealyticum and Ureaplasma microti: The target genes respectively have: (I), a nucleotide sequence for identifying Ureaplasma urealyticum as shown in SEQ ID NO.11, a nucleotide sequence for identifying Ureaplasma microti as shown in SEQ ID NO.12; and / or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of (I), (II) or (III).
2. Primer-probe combination, It is characterized in that The primer-probe combination comprises: (I), an upstream primer for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.1; and A downstream primer for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.2; and A probe for detecting gonococci having a nucleotide sequence as shown in SEQ ID NO.3; and / or (II), an upstream primer for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.4; and A downstream primer for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.5; and A probe for detecting Ureaplasma microti having a nucleotide sequence as shown in SEQ ID NO.6; and / or (III), an upstream primer for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.4; and A downstream primer for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.5; and A probe for detecting Ureaplasma urealyticum having a nucleotide sequence as shown in SEQ ID NO.7; or (IV) a nucleotide sequence encoding the same protein as the nucleotide sequence shown in any one of (I) to (III) but different from the nucleotide sequence shown in any one of (I) to (III) due to the degeneracy of the genetic code; or (V) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in any one of (I) to (IV), and a nucleotide sequence having the same or similar function as the nucleotide sequence shown in any one of (I) to (IV); or (VI) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of any one of (I) to (V).
3. The primer-probe combination according to claim 2, It is characterized in that Also included are primer pairs and probes for amplifying and detecting an internal standard gene; The internal standard gene includes one or more of β-globin, RNase P gene, Actin or GAPDH.
4. The primer-probe combination according to claim 2 or 3, It is characterized in that The probe includes a fluorescent group; the fluorescent group includes one or more of FAM, HEX, ROX, VIC, CY5 or Cy5.
5.
5. Use of the primer-probe combination according to any one of claims 2 to 4 in the preparation of a reagent or kit for detecting and / or identifying Neisseria gonorrhoeae, Ureaplasma parvum or Ureaplasma urealyticum.
6. Use of the primer-probe combination according to any one of claims 2 to 4 in the preparation of a reagent or a kit for detecting genital tract inflammation.
7. Combined reagents, It is characterized in that The method comprises the primer-probe combination according to any one of claims 2 to 4.
8. Test kit, It is characterized in that Including any of the following items and PCR reaction reagents: (I) a primer-probe combination as described in any one of claims 2 to 4; and / or (II) The combined reagent according to claim 7.
9. The kit according to claim 8, It is characterized in that The PCR reaction reagents include dNTPs, DNA polymerase, PCR enhancer, and enzyme activator.
10. The kit according to claim 9, It is characterized in that The PCR enhancer includes one or more of DMSO, ammonium sulfate, and betaine; The enzyme activator includes magnesium ions, manganese ions or a combination thereof.
